Similar Posts
42 Code of Federal Regulations Part 8 Opioid Treatment Programs Certification
ByAdminAdmin 02/28/2022Title 42–Public Health CHAPTER I–PUBLIC HEALTH SERVICE, DEPARTMENT OF HEALTH AND HUMAN SERVICES PART 8–CERTIFICATION OF OPIOID TREATMENT PROGRAMS Subpart A–Accreditation Sec. 8.1 Scope. 8.2 Definitions. 8.3 Application for approval as an accreditation body. 8.4 Accreditation body responsibilities. 8.5 Periodic evaluation of accreditation bodies. 8.6 Withdrawal of approval of accreditation bodies. Subpart B–Certification and Treatment Standards 8.11 Opioid treatment program certification. 8.12 Federal…
Methadone Take Home Bottle Recall
ByAdminAdmin 02/17/2023The intent of Bottle Recall initially was to be able to allow patients take home medication and to insure that methadone is not diverted to the streets. However, methadone programs have been giving patients take home medication for years without a serious methadone diversion problem. Furthermore numerous studies have demonstrated that methadone is not a…
Publication
ByAdminAdmin 12/10/2022The Methadone Alliance. Euromethwork Newsletter Mar. 2000, Issue 18. The Methadone Alliance supports people who receive prescribed drugs for the treatment of their drug dependency. We are users and sympathetic professionals working together as equals in a unique initiative to give drug users a voice in the drug policy debate. The Methadone Alliance actively promotes…
Hot Topic Round Table Tuesday, October 9th 2 P.M. Administrative Detox: Necessary Use or Abuse
ByAdminAdmin 04/17/2023Joe Neuberger, Delaware NAMA James DePasquale, Long Beach Patient Committee This roundtable examined the practice of “administrative detoxification” from programs, and explored the conflicts between what programs often perceive as a necessary evil and patients often perceive as a source of anxiety and constant threat to their treatment. Should administrative detox even be program policy…
FDA Announces Labeling Changes Following Cardiac Adverse Events With Addiction Drug
ByAdminAdmin 03/17/2023FDA Talk Paper April 20, 2001 T01-15 Print Media: 301-827-6242 Broadcast Media: 301-827-3434 Consumer Inquiries: 888-INFO-FDA The FDA is strengthening warnings to physicians about serious cardiac adverse events associated with Orlaam (levomethadyl acetate HC), a drug for opiate addiction treatment. FDA has changed the Orlaam labeling to increase the strength of the warnings and to…
Commentary on the NIH Consensus Development Statement(1) from the Meeting on November 17-19, 1997 Effective Medical Treatment of Heroin Addiction
ByAdminAdmin 02/26/2023The National Alliance of Methadone Advocates supports the NIH Consensus Statement on Effective Treatment of Heroin Addiction that was facilitated by the National Institute on Drug Abuse and the National Institute of Health. The imprecate of this special statement should be understood in order to realize the impact that it can have on methadone maintenance…